Karyopharm Therapeutics
KPTI
KPTI
137 hedge funds and large institutions have $145M invested in Karyopharm Therapeutics in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
137
Holders Change
+8
Holders Change %
+6.2%
% of All Funds
2.16%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
30
Increased
43
Reduced
41
Closed
22
Calls
$613K
Puts
$242K
Net Calls
+$371K
Net Calls Change
-$148K
Top Buyers
| 1 |
BlackRock
New York
|
+$4.41M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$4.27M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.17M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.11M |
| 5 |
Millennium Management
New York
|
+$2.04M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$14.3M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$6.3M |
| 3 |
Rafferty Asset Management
New York
|
-$3.55M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.26M |
| 5 |
Barclays
London,
United Kingdom
|
-$3.12M |
